Food and Drug Administration
recently expanded the approved use of Xgeva (denosumab) to treat adults and
some adolescents with giant cell tumor of the bone (GCTB), a rare and usually
non-cancerous tumor. U.S.
GCTB generally occurs in adults between the ages of 20 and 40 years. In most cases, GCTB does not spread to other parts of the body but destroys normal bone as it grows, causing pain, limited range of motion and bone fractures. Rarely, GCTB can transform into a cancerous tumor and spread to the lungs.
Xgeva is a monoclonal antibody that binds to RANKL, a protein essential for maintenance of healthy bone. RANKL is also present in GCTB. Xgeva is intended for patients whose GCTB cannot be surgically removed or when surgery is likely to result in severe morbidity, such as loss of limbs or joint removal. It should only be used in adolescents whose bones have matured.
Xgeva was approved in 2010 to prevent fractures when cancer has spread to the bones.
For more information: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm356528.htm